Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReFOCUS: EGCG in Pre-Frail and Frail Older Cancer Survivors
NCT04553666Phase 2Completed
- Sponsor
- University of Rochester
- Start
- Apr 2021
- Primary completion
- Aug 2023
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epigallocatechin gallate in frailty syndrome and inflammation (2 arms), sponsored by University of Rochester. Primary endpoints: Recruitment Feasibility: Rates of Consent at 0 weeks, Recruitment Feasibility: Rates of Randomization at 0 weeks and 3 more. Started Apr 2021; status: completed.
02
Drugs
epigallocatechin gallate
03
Conditions
frailty syndromeinflammation
Beyond the preview
Go deeper on NCT04553666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04553666.